As CEO Michael Goettler provides an update on the progress made by Viatris in its first year as a combined company, he also offers Generics Bulletin hints as to the detailed strategy that will be unveiled at the firm’s upcoming investor day and explains how biosimilars – including interchangeable Semglee (insulin glargine) – and complex generics are important components of the firm’s future growth plans.

Viatris provided several key updates for its biosimilar pipeline during the company’s Q3 earnings call, including for its biosimilar Eylea and Botox candidates, as well as disclosing another key early-stage asset.

Prime Therapeutics, the large PBM serving tens of millions of members, insisted it was “not beholden to rebates” as it joined Express Scripts in announcing plans to move Viatris/Biocon’s interchangeable biosimilar insulin glargine products to its preferred national formulary.